RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor

An intraductal papillary mucinous neoplasm (IPMN) is a common pancreatic precursor lesion, and it often harbors mutations in KRAS, GNAS, and RNF43. To clarify the molecular profiles of IPMNs, we conducted mutation analysis of KRAS, GNAS, and RNF43 in 61 IPMN formalin-fixed, paraffin-embedded (FFPE)...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao Yan Chang, Yan Wu, Ying Jiang, Peng Yan Wang, Jie Chen
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/1457452
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568599377608704
author Xiao Yan Chang
Yan Wu
Ying Jiang
Peng Yan Wang
Jie Chen
author_facet Xiao Yan Chang
Yan Wu
Ying Jiang
Peng Yan Wang
Jie Chen
author_sort Xiao Yan Chang
collection DOAJ
description An intraductal papillary mucinous neoplasm (IPMN) is a common pancreatic precursor lesion, and it often harbors mutations in KRAS, GNAS, and RNF43. To clarify the molecular profiles of IPMNs, we conducted mutation analysis of KRAS, GNAS, and RNF43 in 61 IPMN formalin-fixed, paraffin-embedded (FFPE) specimens. The mutation rates of codons 12, 13, and 61 in KRAS and codon 201 in GNAS were detected by Sanger sequencing. Next-generation sequencing was performed on RNF43, and the results were further verified by Sanger sequencing. We identified KRAS and GNAS mutations in 35 (57%) and 40 (66%) IPMN cases, respectively. GNAS mutations were significantly correlated with the morphologic subtype (P<0.001) and were more prevalent in the intestinal subtype (93%) than in the gastric (55%) and pancreatobiliary subtypes (44%) but were absent in the oncocytic subtype. RNF43 mutations were found in 5 cases (8%), all of which occurred in high-grade dysplasia and invasive lesions (2/5 and 3/5). All 5 cases harboring RNF43 mutations also exhibited GNAS mutations. RNF43 mutations were associated with a worse prognosis in invasive IPMN patients (P=0.002), while KRAS and GNAS mutations did not affect the prognosis of patients.
format Article
id doaj-art-cce02c6bd2f74447b1d13dc1e06b2312
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-cce02c6bd2f74447b1d13dc1e06b23122025-02-03T00:58:49ZengWileyGastroenterology Research and Practice1687-61211687-630X2020-01-01202010.1155/2020/14574521457452RNF43 Mutations in IPMN Cases: A Potential Prognostic FactorXiao Yan Chang0Yan Wu1Ying Jiang2Peng Yan Wang3Jie Chen4Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing 100730, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing 100730, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing 100730, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing 100730, ChinaDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing 100730, ChinaAn intraductal papillary mucinous neoplasm (IPMN) is a common pancreatic precursor lesion, and it often harbors mutations in KRAS, GNAS, and RNF43. To clarify the molecular profiles of IPMNs, we conducted mutation analysis of KRAS, GNAS, and RNF43 in 61 IPMN formalin-fixed, paraffin-embedded (FFPE) specimens. The mutation rates of codons 12, 13, and 61 in KRAS and codon 201 in GNAS were detected by Sanger sequencing. Next-generation sequencing was performed on RNF43, and the results were further verified by Sanger sequencing. We identified KRAS and GNAS mutations in 35 (57%) and 40 (66%) IPMN cases, respectively. GNAS mutations were significantly correlated with the morphologic subtype (P<0.001) and were more prevalent in the intestinal subtype (93%) than in the gastric (55%) and pancreatobiliary subtypes (44%) but were absent in the oncocytic subtype. RNF43 mutations were found in 5 cases (8%), all of which occurred in high-grade dysplasia and invasive lesions (2/5 and 3/5). All 5 cases harboring RNF43 mutations also exhibited GNAS mutations. RNF43 mutations were associated with a worse prognosis in invasive IPMN patients (P=0.002), while KRAS and GNAS mutations did not affect the prognosis of patients.http://dx.doi.org/10.1155/2020/1457452
spellingShingle Xiao Yan Chang
Yan Wu
Ying Jiang
Peng Yan Wang
Jie Chen
RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor
Gastroenterology Research and Practice
title RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor
title_full RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor
title_fullStr RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor
title_full_unstemmed RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor
title_short RNF43 Mutations in IPMN Cases: A Potential Prognostic Factor
title_sort rnf43 mutations in ipmn cases a potential prognostic factor
url http://dx.doi.org/10.1155/2020/1457452
work_keys_str_mv AT xiaoyanchang rnf43mutationsinipmncasesapotentialprognosticfactor
AT yanwu rnf43mutationsinipmncasesapotentialprognosticfactor
AT yingjiang rnf43mutationsinipmncasesapotentialprognosticfactor
AT pengyanwang rnf43mutationsinipmncasesapotentialprognosticfactor
AT jiechen rnf43mutationsinipmncasesapotentialprognosticfactor